deltatrials
Terminated PHASE2 INTERVENTIONAL 5-arm NCT04614246

Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb (SCHUMANN)

A Randomized, Double-blind, Open for Active Comparator, Parallel-group, Multicenter Phase 2b Study to Assess the Efficacy and Safety of Three Different Doses of P2X3 Antagonist (BAY1817080) Versus Placebo and Elagolix 150 mg in Women With Symptomatic Endometriosis

Sponsor: Bayer

Conditions Endometriosis
Updated 22 times since 2020 Last updated: Jul 28, 2023 Started: Jan 29, 2021 Primary completion: Jan 17, 2022 Completion: May 3, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study terminated by Sponsor

This PHASE2 trial investigates Endometriosis and is currently terminated or withdrawn. Bayer leads this study, which shows 22 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Jun 2023 · 11 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 4 months · monthly snapshot

Change History

22 versions recorded
  1. Feb 2026 — Present [monthly]

    Terminated PHASE2

  2. Sep 2025 — Feb 2026 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. Sep 2023 — Jul 2024 [monthly]

    Terminated PHASE2

Show 17 earlier versions
  1. Jul 2023 — Sep 2023 [monthly]

    Terminated PHASE2

  2. Jun 2023 — Jul 2023 [monthly]

    Terminated PHASE2

    Status: CompletedTerminated

  3. Jul 2022 — Jun 2023 [monthly]

    Completed PHASE2

  4. Jun 2022 — Jul 2022 [monthly]

    Completed PHASE2

    Status: RecruitingCompleted

  5. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  6. Mar 2022 — May 2022 [monthly]

    Recruiting PHASE2

  7. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  8. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  9. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  10. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  11. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  12. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  13. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2

  14. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  15. Feb 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE2

  16. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE2

  17. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .